Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes

Authors :: Kimberly E. Hawkins
John R. Wingard
Elizabeth Wise
Christopher R. Cogle
John W. Hiemenz
Leslie Pettiford
Daniel Turner
Christina Cline
William S. May
Raphael C. Bosse
Bradley Collins
Jan S. Moreb
Randall Brown
Zackary Beachamp
Fatih M. Uckun
Maxim Norkin
Jack W. Hsu
Source :: British Journal of Haematology. 189
Publication Year :: 2020
Publisher :: Wiley, 2020.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Myelodysplastic syndromes
Refractory Disease
Myeloid leukemia
Hematology
medicine.disease
Combretastatin A1 Diphosphate
Clinical trial
Refractory
Internal medicine
medicine
Single agent
In patient
business

Full Text Access

Tools